Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
222 participants
INTERVENTIONAL
2019-01-22
2020-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
5 days
oral oseltamivir 75 mg once daily for 5 days post-exposure
Oseltamivir Oral Capsule for 5 days post-exposure
Patients will receive oseltamivir for 5 days after last influenza exposure.
10 days
oral oseltamivir 75 mg once daily for 10 days post-exposure
Oseltamivir Oral Capsule for 10 days post-exposure
Patients will receive oseltamivir for 10 days after last influenza exposure.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oseltamivir Oral Capsule for 5 days post-exposure
Patients will receive oseltamivir for 5 days after last influenza exposure.
Oseltamivir Oral Capsule for 10 days post-exposure
Patients will receive oseltamivir for 10 days after last influenza exposure.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* exposure to influenza during hospitalization
* risk factors for influenza complications
* consent for participation obtained
Exclusion Criteria
* hematological malignancy
* hospitalized in intensive care unit
* refusal to participate
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Centre Ljubljana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daša Stupica
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical center Ljubljana
Ljubljana, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lepen L, Blagus R, Veluscek M, Saletinger R, Petrovec M, Bajrovic FF, Stupica D. Five-Day vs 10-Day Postexposure Chemoprophylaxis With Oseltamivir to Prevent Hospital Transmission of Influenza: A Noninferiority Randomized Open-Label Study. Open Forum Infect Dis. 2020 Jun 19;7(8):ofaa240. doi: 10.1093/ofid/ofaa240. eCollection 2020 Aug.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Tamiflu 2019
Identifier Type: -
Identifier Source: org_study_id